Short answer
Vanda Pharmaceuticals Inc. (VNDA) filed an 8-K current report with the SEC on October 28, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results covered quarter ended September 30, 2026.
Vanda Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results covered quarter ended September 30, 2026
- Earnings call and press release issued October 28, 2026
- Investor focus: commercial product performance and pipeline development timelines
- Full financial results and management commentary in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $69.8M, up 24% YoY, led by Fanapt $38.8M and HETLIOZ $21.7M including $7.0M of timing-related shipments
- Operating expenses $93.3M, down 18% sequentially, supporting management’s expectation for further cost reductions
- Net loss $22.6M, or $0.37 per diluted share, while cash and securities fell to $140.5M after $123.4M depletion year-to-date
- BYSANTI launch expected Q4 2026, adding a near-term commercial catalyst alongside NEREUS revenue growth
- Quimilza FDA decision targeted December 12, 2026, creating a significant binary regulatory catalyst for GPP indication
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vanda Pharmaceuticals Inc. 8-K filings
Get the next VNDA 8-K as it lands
Follow VNDA for push alerts, or ask the research agent what this filing means.